Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$1.45 CAD
Change Today 0.00 / 0.00%
Volume 61.9K
BTI On Other Exchanges
Symbol
Exchange
Venture
As of 3:58 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

bioasis technologies inc (BTI) Snapshot

Open
C$1.43
Previous Close
C$1.45
Day High
C$1.45
Day Low
C$1.40
52 Week High
03/16/15 - C$1.50
52 Week Low
10/15/14 - C$0.75
Market Cap
63.8M
Average Volume 10 Days
190.7K
EPS TTM
C$-0.08
Shares Outstanding
44.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOASIS TECHNOLOGIES INC (BTI)

Related News

No related news articles were found.

bioasis technologies inc (BTI) Related Businessweek News

No Related Businessweek News Found

bioasis technologies inc (BTI) Details

biOasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing Transcend and Transcend pep platforms for the transport of therapeutic agents across the blood brain barrier for the treatment of brain cancer, tumors, neurodegenerative diseases, metabolic diseases, small-interfering RNA gene therapy, and stroke and traumatic brain injury. The company owns approximately 30 U.S. and foreign patents/applications related to p97 as a blood-brain barrier delivery vector and as a biomarker for Alzheimer's disease. It has collaboration agreements with Shire Human Genetic Therapies Inc., AbbVie Inc., Medimmune Limited, and UCB Pharma SA. The company was incorporated in 2006 and is headquartered in Richmond, Canada.

Founded in 2006

bioasis technologies inc (BTI) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: C$166.0K
Compensation as of Fiscal Year 2014.

bioasis technologies inc (BTI) Key Developments

biOasis Technologies Inc. Releases Results from an Ischemic Stroke Model with Transcend BBB Carrier Peptide (MTfp)

biOasis Technologies Inc. announced the results from an animal ischemic stroke model performed at the National Research Council Canada with the biOasis Transcend carrier peptide, MTfp and siRNA (MTfp-siRNA). Two key therapeutic effects were shown with MTfp-siRNA; A high degree of reduction of the area of blood vessel infarct and improvement of overall brain activity as determined by neurological scoring. Key Findings of Ischemic Stroke Model Treated with MTfp-siRNA: (1) The area of infarct (damage) was highly reduced in the animals treated with MTfp-siRNA. Brain images revealed significantly less stroke damage in brain sections from animals treated with the MTfp-siRNA when compared to the same brain regions in the control animals. The images show that there is more stroke damage (white areas) in the five sections from control animals (Left Panel) when compared to the same brain regions in the animals with stroke treated with the MTfp-siRNA (Right Panel). (2) Thirty-minutes after induction of stroke, the neurological scores of the animals treated with the MTfp-siRNA were significantly better than those of control animals. At 24 hours, controls animals demonstrated a slight improvement in neurological scores while MTfp-siRNA treated animals showed a vast improvement and exhibited nearly normal neurological scores.

BIOASIS TECHNOLOGIES INC. Announces the Results from an Animal Ischemic Stroke Model

BIOASIS TECHNOLOGIES INC. announced the results from an animal ischemic stroke model performed at the National Research Council Canada with the biOasis Transcend carrier peptide, MTfp and siRNA (MTfp-siRNA). Two key therapeutic effects were shown with MTfp-siRNA; A high degree of reduction of the area of blood vessel infarct and improvement of overall brain activity as determined by neurological scoring. Ischemic stroke is the most common type of stroke in humans and an animal model that mimics stroke was chosen to establish the effectiveness of MTfp-siRNA treatment administered immediately prior to induction of ischemic stroke. Key Findings of Ischemic Stroke Model Treated with MTfp-siRNA: The area of infarct (damage) was highly reduced in the animals treated with MTfp-siRNA. Brain images revealed significantly less stroke damage in brain sections from animals treated with the MTfp-siRNA when compared to the same brain regions in the control animals.Thirty-minutes after induction of stroke, the neurological scores of the animals treated with the MTfp-siRNA were significantly better than those of control animals. At 24 hours, controls animals demonstrated a slight improvement in neurological scores while MTfp-siRNA treated animals showed a vast improvement and exhibited nearly normal neurological scores.

biOasis Technologies Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

biOasis Technologies Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BTI:CN C$1.45 CAD 0.00

BTI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BTI.
View Industry Companies
 

Industry Analysis

BTI

Industry Average

Valuation BTI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 22.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOASIS TECHNOLOGIES INC, please visit www.bioasis.ca. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.